CSIMarket


Integrated Biopharma Inc  (INBP)
Other Ticker:  
 
 

INBP's Net Income Growth by Quarter and Year

Integrated Biopharma Inc's Net Income results by quarter and year




INBP Net Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter June - 4.51 1.90 0.36
III Quarter March - 1.24 0.94 0.92
II Quarter December - 1.22 0.96 0.25
I Quarter September 0.52 1.04 0.31 0.16
FY   0.52 8.01 4.11 1.69



INBP Net Income first quarter 2021 Y/Y Growth Comment
Integrated Biopharma Inc reported drop in Net Income in the first quarter by -50.38% to $ 0.52 millions, from the same quarter in 2020.
The fall in the first quarter Integrated Biopharma Inc's Net Income compares unfavorably to the Company's average Net Income doubling of 193.53%.

Looking into first quarter results within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Net Income growth. While Integrated Biopharma Inc' s Net Income meltdown of -50.38% ranks overall at the positon no. 1818 in the first quarter.




INBP Net Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter June - 137.37 % 427.78 % -63.27 %
III Quarter March - 31.91 % 2.17 % 109.09 %
II Quarter December - 27.08 % 284 % -
I Quarter September -50.38 % 235.48 % 93.75 % -
FY   - 94.89 % 143.2 % 89.89 %

Financial Statements
Integrated Biopharma Inc's first quarter 2021 Net Income $ 0.52 millions INBP's Income Statement
Integrated Biopharma Inc's first quarter 2020 Net Income $ 1.04 millions Quarterly INBP's Income Statement
New: More INBP's historic Net Income Growth >>


INBP Net Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter June - 263.71 % 102.13 % -60.87 %
III Quarter March - 1.64 % -2.08 % 268 %
II Quarter December - 17.31 % 209.68 % 56.25 %
I Quarter September -88.56 % -45.26 % -13.89 % -83.67 %
FY (Year on Year)   - 94.89 % 143.2 % 89.89 %




Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #134
Overall #1818

Net Income Y/Y Growth Statistics
High Average Low
1309.43 % 193.53 % -63.23 %
(Jun 30 2016)   (Jun 30 2019)
Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #134
Overall #1818
Net Income Y/Y Growth Statistics
High Average Low
1309.43 % 193.53 % -63.23 %
(Jun 30 2016)   (Jun 30 2019)

Net Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Integrated Biopharma Inc's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
2163.64 % 194.91 % -88.55 %
(Jun 30 2016)  


INBP's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Integrated Biopharma Inc reported fall in Net Income sequentially by -88.56% to $ 0.52 millions, from $ 4.51 millions achived in the previous reporting period.

But that's not important concern, as I. Quarter Net Income always gravitate to slow in the I. Quarter Marine De Smet, Biotechnology & Pharmaceuticals industry insider noted.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Net Income quarter on quarter growth. While Integrated Biopharma Inc's Net Income growth quarter on quarter, overall rank is 1759.


Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #124
Overall #1759
Net Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #15
Healthcare Sector #124
Overall #1759
Net Income Q/Q Growth Statistics
High Average Low
2163.64 % 194.91 % -88.55 %
(Jun 30 2016)  


INBP's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Integrated Biopharma Inc reported fall in Net Income from the previous quarter by -88.56% to $ 0.52 millions, from $ 4.51 millions declared in the previous reporting period.

If you evaluate current shortcoming in the quarter, you should assume, that frequently I. Quarter Net Income emerge softer relative to the forth quarter, Marine De Smet, Biotechnology & Pharmaceuticals industry insider mentioned.

Within Biotechnology & Pharmaceuticals industry 14 other companies have achieved higher Net Income quarter on quarter growth. While Integrated Biopharma Inc's Net Income growth quarter on quarter, overall rank is 1759.


Integrated Biopharma Inc's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
Cumulative Net Income 12 Months Ending $ 7.49 $ 8.01 $ 5.41 $ 5.10 $ 4.84
Y / Y Net Income Growth (TTM) 54.81 % 95.06 % 110.63 % 99.77 % 162.74 %
Year on Year Net Income Growth Overall Ranking # 638 # 548 # 343 # 61 # 121
Seqeuential Net Income Change (TTM) -6.55 % 48.2 % 5.98 % 5.48 % 17.75 %
Seq. Net Income Growth (TTM) Overall Ranking # 1497 # 402 # 1351 # 230 # 398




Cumulative Net Income growth Comment
With the quarterly Net Income reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Net Income were $ 7 millions, company would post below average annual Net Income growth of 17.75% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Net Income growth from the 4.51% growth in Jun 30 2021.

In the Healthcare sector 37 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 548 to 638.

Net Income TTM Q/Q Growth Statistics
High Average Low
262.88 %
18.96 %
-84.7 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 38
Overall # 638

Net Income TTM Y/Y Growth Statistics
High Average Low
981.6 %
107.4 %
-79.44 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 106
S&P 500 # 1497
Cumulative Net Income growth Comment
With the quarterly Net Income reported in the Sep 30 2021 period, Integrated Biopharma Inc's cumulative twelve months Net Income were $ 7 millions, company would post below average annual Net Income growth of -79.44% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Integrated Biopharma Inc's Net Income growth from the 4.51% growth in Jun 30 2021.

In the Healthcare sector 37 other companies have achieved higher trailing twelve month Net Income growth. While Net Income growth total ranking has deteriorated compare to previous quarter from 548 to 638.

Net Income TTM Q/Q Growth Statistics
High Average Low
262.88 %
18.96 %
-84.7 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 15
Healthcare Sector # 38
Overall # 638

Net Income TTM Y/Y Growth Statistics
High Average Low
981.6 %
107.4 %
-79.44 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 15
Sector # 106
S&P 500 # 1497




Other Net Income Growth
Biotechnology & Pharmaceuticals Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
INBP's Net Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for INBP's Competitors
Net Income Growth for Integrated Biopharma Inc's Suppliers
Net Income Growth for INBP's Customers

You may also want to know
INBP's Annual Growth Rates INBP's Profitability Ratios INBP's Asset Turnover Ratio INBP's Dividend Growth
INBP's Roe INBP's Valuation Ratios INBP's Financial Strength Ratios INBP's Dividend Payout Ratio
INBP's Roa INBP's Inventory Turnover Ratio INBP's Growth Rates INBP's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Net Income for the quarter ending Sep 30 2021
Dexcom Inc -1.80%$ -1.801 millions
Owens and Minor Inc -4.24%$ -4.236 millions
United Therapeutics Corporation-4.96%$ -4.965 millions
Amgen Inc -6.78%$ -6.779 millions
Quidel Corporation-7.11%$ -7.111 millions
Eli Lilly And Company-8.13%$ -8.135 millions
Abiomed Inc -8.45%$ -8.455 millions
Universal Health Services Inc -10.13%$ -10.126 millions
U S Physical Therapy Inc-10.40%$ -10.404 millions
Quest Diagnostics Inc-10.83%$ -10.829 millions
Lemaitre Vascular Inc-13.43%$ -13.430 millions
Vyne Therapeutics Inc -13.87%$ -13.875 millions
Semler Scientific inc -14.71%$ -14.714 millions
Pro dex Inc -15.89%$ -15.889 millions
Laboratory Corporation Of America Holdings-16.47%$ -16.470 millions
Bristol Myers Squibb Co-17.36%$ -17.359 millions
Electromed Inc -17.98%$ -17.984 millions
Nature s Sunshine Products inc -23.87%$ -23.867 millions
Immune Therapeutics Inc -23.97%$ -23.971 millions
Petmed Express Inc-24.52%$ -24.524 millions
Co diagnostics Inc -27.05%$ -27.051 millions
Elite Pharmaceuticals Inc -27.59%$ -27.587 millions
Collegium Pharmaceutical inc -28.71%$ -28.708 millions
Biodelivery Sciences International Inc -28.92%$ -28.925 millions
Stryker Corp-29.47%$ -29.469 millions
Fitlife Brands Inc -31.61%$ -31.611 millions
Hologic Inc-33.29%$ -33.293 millions
Msa Safety Inc-33.33%$ -33.332 millions
Steris Plc-34.32%$ -34.321 millions
Viemed Healthcare Inc -36.20%$ -36.198 millions


       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

CANB's Profile

Stock Price

CANB's Financials

Business Description

Fundamentals

Charts & Quotes

CANB's News

Suppliers

CANB's Competitors

Customers & Markets

Economic Indicators

CANB's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Cryptocurrencies

Sectors & Industries

Commodities

Currencies

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071